Loading...
Market
Story
FDA Approves Merck's 21-valent Capvaxive Pneumococcal Vaccine for Adults
Jun 17, 2024, 09:25 PM
The U.S. Food and Drug Administration (FDA) has approved Merck's new 21-valent pneumococcal vaccine, Capvaxive, designed to protect adults against 21 strains of pneumococcus bacteria. This vaccine is the first of its kind specifically targeting adults and covers eight serotypes of Streptococcus pneumoniae not addressed by other vaccines. The approval sets the stage for a competitive battle between Merck and Pfizer, whose pneumococcal vaccine franchise is one of its largest. The Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) are expected to provide recommendations on its use next week. Capvaxive is also designed to protect against serious infections.
View original story
Similar markets
Approved in all major markets • 25%
Approved in some major markets • 25%
Not approved in any major markets • 25%
Approval status pending • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Capvaxive leads • 33%
Prevnar 20 leads • 33%
Equal market share • 33%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
Below $10 billion • 25%
$10 billion - $15 billion • 25%
$15 billion - $20 billion • 25%
Above $20 billion • 25%
Capvaxive preferred • 33%
Prevnar 20 preferred • 33%
No preference • 33%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%